Previous Close | 1.5900 |
Open | 1.5900 |
Bid | 2.0700 |
Ask | 2.2200 |
Strike | 180.00 |
Expire Date | 2024-12-20 |
Day's Range | 1.5900 - 1.5900 |
Contract Range | N/A |
Volume | |
Open Interest | 11 |
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.